Target intelligence / Profile preview

Long intergenic non-protein coding RNA 2363 (LINC02363)

Target
LINC02363
Molecular classification
Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01

Overview

Long intergenic non-protein coding RNA 2363 (LINC02363) is a lincRNA gene found on chromosome 4q35.1[2]. Its transcripts do not encode proteins and are classified as long non-coding RNAs, which are typically over 200 nucleotides in length and do not overlap known protein-coding regions[1][3][9]. The precise molecular and biological functions of LINC02363 remain to be determined, but it is part of the growing class of lincRNAs implicated in regulating gene expression through various epigenetic and post-transcriptional mechanisms[3][5][7][9]. Early research links LINC02363 to disease states such as sepsis—where it may serve as a biomarker—and potentially lung injury and perinatal hypoxic-ischemic encephalopathy[6][8][10]. There are no known drugs targeting LINC02363, but it is of interest in ongoing studies of non-coding RNA biology and biomarker development.

Other names
LINC02363Long intergenic non-protein coding RNA 2363
02

Mechanism of action

Not applicable; no drugs targeting LINC02363 are reported. If its function as a biomarker or regulator is confirmed, mechanisms would likely involve modulation of gene expression processes[8][10].

03

Biological functions

Putative regulation of gene expression (cis- or trans-acting)Epigenetic modulationChromatin structure remodeling (general function of some lincRNAs; specific functions for LINC02363 are not yet fully characterized)Potential molecular signaling in response to stimuli
04

Disease associations

Sepsis (as a potential biomarker for early diagnosis and possibly an intervention target)Potential association with acute lung injuryDifferential expression in neonates with hypoxic-ischemic conditions, possibly linked to adverse outcomes
05

Safety considerations

None specifically reported. As an RNA molecule, targeting or modulating it could theoretically affect gene regulatory networks, but no therapeutic strategies or safety profiles have been established[1][8][10].
06

Interacting drugs

None known; no approved or investigational drugs reported to interact directly with LINC02363
07

Biomarkers

Potential biomarker for early diagnosis and monitoring of sepsisDifferential expression in neonatal hypoxic-ischemic encephalopathy (proposed as a disease risk/diagnostic biomarker)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 2363 (LINC02363).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 2363 (LINC02363).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call